Please assess the completion status of the following clinical trial:

Trial Title: Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with moderate to severe plaque psoriasis on etanercept treatment according to the Summary of Product Characteristics (SmPC), and applicable local guidelines~* Subjects for whom the decision has already been made to initiate treatment with etanercept~Exclusion Criteria:~* Sepsis or risk of sepsis~* Current or recent infections, including chronic or localized, e.g. tuberculosis (TB) infection~* Vaccination with live vaccine in last 4 weeks, or expected to require such vaccination during the course of the study~* Pre-existing or recent onset CNS demyelinating disease.~* Class III or IV congestive heart failure as defined by the New York Heart Association classification or uncompensated congestive heart failure.~* Previous or ongoing treatment with etanercept~* Participation in other clinical or observational studies.~* Patients with psoriatic arthritis requiring continuous etanercept treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: None): Patients with moderate to severe plaque psoriasis

Based on this trial design, predict the completion outcome and termination type (if applicable).